Search

Your search keyword '"Yan, Qingna"' showing total 15 results
Start Over Author "Yan, Qingna"
15 results on '"Yan, Qingna"'

7. Metabolomics Study of Isocaloric Different Dietary Patterns on the Life Span in Healthy Population

Author

Zhang,Cong, Yan,Qingna, Zhu,Qiushuang, Liu,Jinxiao, Dong,Yuanjie, Li,Yuqiao, Wang,Ruohua, Tang,Xuanfeng, Lv,Xinyi, Li,Xiaoqing, Cai,Yunjiang, Niu,Yucun, Zhang,Cong, Yan,Qingna, Zhu,Qiushuang, Liu,Jinxiao, Dong,Yuanjie, Li,Yuqiao, Wang,Ruohua, Tang,Xuanfeng, Lv,Xinyi, Li,Xiaoqing, Cai,Yunjiang, and Niu,Yucun

Abstract

Cong Zhang,1,2,* Qingna Yan,1,* Qiushuang Zhu,1,* Jinxiao Liu,1,* Yuanjie Dong,1 Yuqiao Li,1 Ruohua Wang,1 Xuanfeng Tang,1 Xinyi Lv,1 Xiaoqing Li,1 Yunjiang Cai,3 Yucun Niu1 1Department of Nutrition and Food Hygiene, Public Health College, Harbin Medical University, Harbin, 150086, People’s Republic of China; 2Center of Disease Control and Prevention of Xishan District, Wuxi, 214000, People’s Republic of China; 3Nursing College of Daqing Campus of Harbin Medical University, Daqing, 163319, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yucun NiuDepartment of Nutrition and Food Hygiene, College of Public Health, Harbin Medical University, 157 Baojian Road, Nangang District, Harbin, 150081, People’s Republic of ChinaTel +86-451-8750-2730Fax +86-451-8750-2885Email niuyucun@163.comPurpose: How to prolong life by diet has been widely concerned. There are many reports about the effects of different dietary patterns on life span, but the results are not consistent. The main reason may be that total energy intake has not been considered. This study aims to explore the effects of isocaloric different dietary patterns on population life span.Materials and Methods: From the data of the follow-up population, eligible participators were divided into normal control (NC) group (28.31% fat, 12.37% protein, 62.30% carbohydrate), isocaloric high-fat (IHF) group (38.39% fat, 12.21% protein, 51.32% carbohydrate), isocaloric high-protein (IHP) group (33.41% fat, 17.10% protein, 52.67% carbohydrate) and isocaloric high-carbohydrate (IHC) group (22.23% fat, 10.52% protein, 70.13% carbohydrate) according to the dietary structure and the age stratification. Global serum metabolic profiling analysis by UPLC−Q-TOF-MS/MS technology, fatty acid and amino acid profiles in serum were determined by GC-MS and UPLC-TQ-MS technology. One-way ANOVA followed by Dunnett post hoc test and receiver operating charac

Published
2021

10. Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non‐EML4‐ALK rearrangements detected from cerebrospinal fluid: A case report.

Author

Li, Zhaona, Li, Pupu, Yan, Bing, Gao, Qiongqiong, Jiang, Xiangli, Zhan, Zhongli, Yan, Qingna, Lizaso, Analyn, and Huang, Chun

Subjects
ADENOCARCINOMA, ANTINEOPLASTIC agents, LUNG tumors, MENINGEAL cancer, METASTASIS, PROTEIN-tyrosine kinase inhibitors, ANAPLASTIC lymphoma kinase, CHEMICAL inhibitors
Abstract

A 47‐year‐old female with ALK‐rearranged lung adenocarcinoma developed leptomeningeal metastasis (LM) after progression on first‐line crizotinib. Alectinib 300 mg was commenced and the patient achieved clinical and radiographic improvements. After nine months of alectinib 300 mg, she started to experience symptomatic LM. Two concurrent non‐EML4‐ALK rearrangements, LOC388942‐ALK and LINC00211‐ALK, were identified from the CSF but not from the plasma samples. With the primary lung lesions remaining stable, the alectinib dose was increased to 600 mg twice daily which alleviated the clinical symptoms of symptomatic LM. After 7.6 months of alectinib 600 mg, the patient again experienced CNS progression. With both CSF and plasma samples revealing no druggable mutations, the alectinib dose was re‐escalated to 900 mg twice daily, resulting in clinical benefits lasting for two months. Her therapy was then switched to lorlatinib which controlled the disease for 8.7 months until her demise. The LINC00211‐ALK fusion, which retains the ALK kinase domain, detected from the CSF was the mechanism of treatment efficacy in this patient. The central nervous system (CNS) has been increasingly recognized as a site of treatment failure in multiple cancers, including non‐small cell lung cancer (NSCLC). Our case demonstrated that alectinib dose‐escalation and lorlatinib overcame ALK inhibitor resistance in the CNS in an ALK‐positive LM patient. Furthermore, we provide the first clinical evidence of the efficacy of sequential ALK inhibitors in targeting LINC00211‐ALK in a patient with LM. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results